Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News |

Request a free trial

July 21, 2008

Is Alimta (Lilly) the answer? (What is the question?)
Analysis of: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor

Individualizing chemotherapy depending on histology (adenocarcinomas) shows that Alimta/CisPlatin appears to be more convenient and less toxic than its stablemate Gemzar.

July 21, 2008

As if Rituxan (Genentech/Biogen) needed another market?
Analysis of: Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation | content.nejm.org
Author: GLG Expert Contributor

For patients with antibodies that may make renal transplants problematic, Rituxan may make them possible!

July 14, 2008

Notice the US is not part of the discussion?
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: GLG Expert Contributor

GSK is discussing drug development with European countries and not the US. Implications???

July 10, 2008

Medicare fee cuts: Saved by someone who may appreciate the significance........
Analysis of: Bill to Block Medicare-Fee Cuts | online.wsj.com
Author: GLG Expert Contributor

Medicare will not cut physicians fees but will cut payments in HMO driven Medicare "advantage" plans. This means that the republicans will be unable to "feather the nest" of their insurer friends!

July 9, 2008

Further evidence that government intervention is around the corner
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Expert Contributor

Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.

July 8, 2008

What ever happens I can assure you the Doctors will be f........
Analysis of: Clash on Preventing Cut to Doctor Payments | online.wsj.com
Author: GLG Expert Contributor

11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?

July 7, 2008

Cost vs Efficacy: A conundrum for insurers, physicians and patients.
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor

Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.

July 3, 2008

Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Expert Contributor

We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.

July 3, 2008

Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: GLG Expert Contributor

This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.

June 30, 2008

The heck with the impact on Roche. How about the patients??
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor

Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 420

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-06T17:45:17.377

GLG News by Lung Cancer Oncologists (US)

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare